Prevalence and prognostic implications of ST-segment deviations from ambulatory Holter monitoring after ST-segment elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention (a Danish Trial in Acute Myocardial Infarction-2 Substudy).
Ambulatory Holter monitoring has been shown to be useful in stratifying cardiovascular risk after acute myocardial infarction. However, it remains unclear whether ST-segment deviations might predict clinical outcomes in a population treated with primary percutaneous coronary intervention (PCI) compared with thrombolysis. Holter monitoring was initiated at discharge from ST-segment elevation myocardial infarction in 958 patients followed for 2,773 patient-years, randomized to immediate revascularization with either fibrinolysis (n=474) or PCI (n=484). The primary end point was all-cause mortality, and the secondary end point was a composite of death, reinfarction, and disabling stroke. The prevalences of ST-segment depression (STd) and ST-segment elevation (STe) were similar in patients treated with fibrinolysis or PCI (both p=NS). During follow-up, 58 patients died (primary PCI vs fibrinolysis hazard ratio 0.74, p=0.25). The secondary end point was reached in 113 patients (primary PCI vs fibrinolysis hazard ratio 0.66, p=0.03). In fibrinolysis-treated patients, mortality and the secondary end point were significantly higher in patients with STe (both end points p<0.001), an association that remained statistically significant after adjustment for age, gender, anterior infarction, beta-blocker treatment, left ventricular systolic function, and STd (p=0.03 and p=0.005, respectively). Significant associations were not observed for STd. In PCI-treated patients, there was no association between either STe or STd and outcome. In conclusion, immediate revascularization with PCI during STe myocardial infarction does not affect the subsequent prevalence of ST-segment deviation compared with fibrinolysis. However, although STe is an independent predictor of mortality and nonfatal major cardiovascular events in patients treated with fibrinolysis, it does not predict outcome after PCI, perhaps because of more complete revascularization.
Idorn
Lars
L
Department of Medical Research, Funen Hospital, Svendborg, and Department of Cardiology, Copenhagen University Hospital, Denmark. larsidorn@hotmail.com
Høfsten
Dan Eik
DE
Wachtell
Kristian
K
Mølgaard
Henning
H
Egstrup
Kenneth
K
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015716:Electrocardiography, Ambulatory; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality* / Q000628:therapy*; D015995:Prevalence; D011379:Prognosis; D012008:Recurrence; D018570:Risk Assessment; D020521:Stroke / Q000453:epidemiology; D016019:Survival Analysis; D015912:Thrombolytic Therapy